Carr ER, Higgins PB, McClenaghan NH, Flatt PR, McCloskey AG (2024) MicroRNA regulation of islet and enteroendocrine peptides: physiology and therapeutic implications for type 2 diabetes
In the tirzepatide pivotal trials specifically, hair loss was reported in 4.9-5.3% of treatment groups compared to just 0.9% on placebo, yielding a relative risk of 5.67
10.1016/j.urolonc.2009.08.001 Urol
*In clinical trials, GLP-1 medcations demonstrate up to 15-20% weight loss
The article explores alternative molecular mechanismsincluding tau protein aggregation, neuroinflammation, synaptic and mitochondrial dysfunction, brain insulin resistance, vascular impairment, and infectious triggersthat may provide better insights into disease progression and resistance to current treatments